Royal Bank of Canada
LGND icon

Royal Bank of Canada’s Ligand Pharmaceuticals LGND Stock Holding History

Royal Bank of Canada’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-48,090
Closed -$1.58M – 6026
2013
Q4 		$1.58M Buy
+48,090
New +$1.57M ﹤0.01% 2473

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Royal Bank of Canada's LGND Position: Q1 2026 in Review

Royal Bank of Canada increased its Ligand Pharmaceuticals (LGND) stake by 2.5% in Q1 2026, buying an estimated $543K and bringing the position to 111,543 shares worth $22.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1378.

Royal Bank of Canada first reported a position in LGND in Q2 2013 and has held it in 49 quarters since. 358 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Royal Bank of Canada held 111,543 shares of Ligand Pharmaceuticals worth $22.3M as of Q1 2026.
  • Royal Bank of Canada bought 2,747 Ligand Pharmaceuticals shares in Q1 2026, an estimated $543K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #1378 holding.
  • Royal Bank of Canada first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • 358 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.